Skip to main content
OTLK
NASDAQ Life Sciences

Outlook Therapeutics Prices $55M Public Offering with Warrants at $0.99

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.841
Mkt Cap
$166.203M
52W Low
$0.161
52W High
$3.39
52W Position info
422% above low
Off High info
75% below high
Rel. Volume info
3.5× avg
Market data snapshot near publication time

OTLK has more than doubled off its 52-week low of $0.161 on elevated volume (3.5× avg).

Summary

Outlook Therapeutics priced a $55 million public offering of 55.6 million shares plus warrants at $0.99 per unit, with net proceeds of about $51.1 million to fund the US launch of LYTENAVA.

Updates

  1. · SEC 8-K — Underwriters exercised their option for 8,333,333 additional warrants. GMS Ventures purchased 2,525,252 shares and warrants; CEO Robert Jahr purchased 151,515 and CFO Lawrence Kenyon purchased 101,010.


Key Events · Financing and Capital Events · OTLK

  • Public Offering Priced

    55,555,556 shares plus warrants to purchase 55,555,556 shares at combined price of $0.99 per share, for total gross proceeds of $55.0 million.

  • Net Proceeds and Use

    Net proceeds of approximately $51.1 million after underwriting discounts and expenses, to fund US commercial launch of LYTENAVA and working capital.

  • Warrant Terms

    Warrants exercisable immediately at $1.10 per share, expire five years from issuance; underwriters have 30-day option for 8,333,333 additional shares/warrants.

  • Dilution Impact

    Offering increases outstanding shares from 187.1 million to 242.7 million, a 29.7% increase; immediate dilution of $0.75 per share to new investors.


Analysis · OTLK · Life Sciences

Outlook Therapeutics is raising $55 million in a public offering of 55.6 million shares plus warrants, priced at $0.99 per unit. The deal is highly dilutive — the offering nearly doubles the current share count of 187 million — but it provides critical capital to fund the US commercial launch of LYTENAVA, which received FDA approval in July 2026. The company had only $11.2 million in cash as of June 30, 2026, and this raise extends its runway into Q2 2027. The warrants, exercisable at $1.10, add further potential dilution if the stock rises. The offering price is below the last reported sale price of $1.10 on August 12, 2026, indicating a discount to market.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, OTLK was trading at $0.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $166.2M. The 52-week trading range was $0.16 to $3.39. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

OTLK - Latest Insights

OTLK
Sep 30, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.5989
Real-time Price: $0.3782 info
Change: -$0.2207 (-37%) info
Market Cap: $91.329M info
OTLK
Sep 18, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.670776
Real-time Price: $0.3782 info
Change: -$0.292576 (-44%) info
Market Cap: $91.329M info
OTLK
Aug 18, 2026, 5:29 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.6982
Real-time Price: $0.3782 info
Change: -$0.320 (-46%) info
Market Cap: $91.329M info
OTLK
Aug 17, 2026, 7:27 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.7973
Real-time Price: $0.3782 info
Change: -$0.4191 (-53%) info
Market Cap: $91.329M info
OTLK
Aug 14, 2026, 7:54 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.790
Real-time Price: $0.3782 info
Change: -$0.4118 (-52%) info
Market Cap: $91.329M info